ctDNA-guided booster treatment after chemo for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old when you sign up.
- You have stage II or III triple-negative breast cancer (a specific breast cancer subtype based on hormone and HER2 test results).
- Your blood ctDNA test is positive after curative surgery and/or after adjuvant chemotherapy.
- You can do cancer-day-to-day activities at a normal level (ECOG 0–2).
- You agree to give blood samples for ctDNA testing every 3 months for up to 5 years.
- You agree to follow standard additional treatments if recommended, like adjuvant chemotherapy and (if indicated) radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (camrelizumab) with chemotherapy (nab-paclitaxel) and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial checks how a blood test that looks for cancer DNA (ctDNA) changes during and after you take capecitabine after early triple-negative breast cancer. It aims to see whether these blood test results can help monitor the chance of the cancer coming back.
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.